Wedbush Maintains Neutral on Vera Therapeutics, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Vera Therapeutics (NASDAQ:VERA) and raises the price target from $21 to $34.

March 21, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Vera Therapeutics and raises the price target from $21 to $34.
The increase in price target from $21 to $34 by a reputable analyst suggests a positive outlook on the company's valuation, potentially leading to increased investor interest and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100